MYE0 logo

MaxCyte DB:MYE0 Stock Report

Last Price

€3.08

Market Cap

€344.0m

7D

-3.1%

1Y

-19.4%

Updated

22 Nov, 2024

Data

Company Financials +

MYE0 Stock Overview

A life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. More details

MYE0 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

MaxCyte, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for MaxCyte
Historical stock prices
Current Share PriceUK£3.08
52 Week HighUK£4.96
52 Week LowUK£2.98
Beta1.16
11 Month Change-7.23%
3 Month Change-13.97%
1 Year Change-19.37%
33 Year Change-60.00%
5 Year Changen/a
Change since IPO-58.10%

Recent News & Updates

Recent updates

Shareholder Returns

MYE0DE Life SciencesDE Market
7D-3.1%0.9%-0.02%
1Y-19.4%2.7%8.2%

Return vs Industry: MYE0 underperformed the German Life Sciences industry which returned 2% over the past year.

Return vs Market: MYE0 underperformed the German Market which returned 7.4% over the past year.

Price Volatility

Is MYE0's price volatile compared to industry and market?
MYE0 volatility
MYE0 Average Weekly Movement5.3%
Life Sciences Industry Average Movement6.1%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.9%
10% least volatile stocks in DE Market2.4%

Stable Share Price: MYE0 has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: MYE0's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998143Maher Masoudwww.maxcyte.com

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols.

MaxCyte, Inc. Fundamentals Summary

How do MaxCyte's earnings and revenue compare to its market cap?
MYE0 fundamental statistics
Market cap€343.97m
Earnings (TTM)-€34.32m
Revenue (TTM)€43.79m

7.9x

P/S Ratio

-10.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MYE0 income statement (TTM)
RevenueUS$45.60m
Cost of RevenueUS$6.39m
Gross ProfitUS$39.21m
Other ExpensesUS$74.94m
Earnings-US$35.74m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.34
Gross Margin85.98%
Net Profit Margin-78.37%
Debt/Equity Ratio0%

How did MYE0 perform over the long term?

See historical performance and comparison